Search results for "Stain"

showing 10 items of 5524 documents

Tetramer visualization of gut-homing gluten-specific T cells in the peripheral blood of celiac disease patients

2007

Tetramers of MHC–peptide complexes are used for detection and characterization of antigen-specific T cell responses, but they require knowledge about both antigenic peptide and the MHC restriction element. The successful application of these reagents in human diseases involving CD4 + T cells is limited. Celiac disease, an intestinal inflammation driven by mucosal CD4 + T cells recognizing wheat gluten peptides in the context of disease-associated HLA-DQ molecules, is an ideal model to test the potential clinical use of these reagents. We investigated whether gluten-specific T cells can be detected in the peripheral blood of celiac disease patients using DQ2 tetramers. Nine DQ2 + patients a…

AdultGlutensT-LymphocytesT cellCellular differentiationBiologyInterferon-gammaHLA-DQ AntigensmedicineHumansInterferon gammaProtein Structure QuaternaryAgedchemistry.chemical_classificationMultidisciplinaryHLA-DQ Antigennutritional and metabolic diseasesCell DifferentiationBreadBiological SciencesMiddle AgedMHC restrictionGlutendigestive system diseasesStainingGastrointestinal TractCeliac DiseasePhenotypemedicine.anatomical_structurechemistryCase-Control StudiesImmunologyLeukocytes MononuclearHoming (hematopoietic)medicine.drugProceedings of the National Academy of Sciences
researchProduct

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

2019

 The urgent need in HCV-infected patients with liver disease mandated the rapid implementation of IFN-free DAA combination therapies following their regulatory approval in 2014 and 2015 without full knowledge of the optimal combinations and regimens. Investigating the evolution of the DAA utilization patterns and treatment outcomes could provide learnings for future situations. This was an analysis of a prospective observational database from the German Hepatitis C Registry (DHC-R) covering a period from May 2014 to September 2015. Adult patients had evidence of chronic HCV GT1 or GT4 infection and were treated with an IFN-free combination regimen of simeprevir (SMV) + sofosbuvir (SOF) or o…

AdultLedipasvirSimeprevirmedicine.medical_specialtyDaclatasvirSustained Virologic ResponseSofosbuvirHepacivirusAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineHumansMedicineProspective StudiesRegistries030212 general & internal medicineFluorenesDasabuvirbusiness.industryGastroenterologyHepatitis C ChronicHepatitis COmbitasvirDrug CombinationsRegimenTreatment OutcomechemistryParitaprevirBenzimidazolesDrug Therapy Combination030211 gastroenterology & hepatologySofosbuvirbusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis.

2015

Background and Aim. The best staining to evaluate liver fibrosis in liver hepatitis is still a debated topic. This study aimed to compare Masson’s trichrome (MT), Sirius Red (SR), and orcein stainings in evaluating liver fibrosis in chronic HCV hepatitis (CHC) with semiquantitative and quantitative methods (Collagen Proportionate Area (CPA) by Digital Image Analysis (DIA)) and correlate them with transient elastography (TE).Methods. Liver stiffness evaluation of 111 consecutive patients with CHC was performed by TE. Semiquantitative staging by Metavir score system and CPA by DIA were assessed on liver biopsy stained with MT, SR, and orcein.Results. MT, SR, and orcein staining showed concord…

AdultLiver CirrhosisMaleCancer ResearchPathologymedicine.medical_specialtyArticle SubjectAdolescentliver fibrosis elastography Digital Image Analysis liver biopsySettore MED/08 - Anatomia PatologicaPathology and Forensic Medicinechemistry.chemical_compoundYoung AdultTrichromeFibrosisImage Processing Computer-AssistedMedicineHumansOrceinSirius RedRC254-282AgedHepatitis ChronicHepatitisSettore MED/12 - Gastroenterologiamedicine.diagnostic_testQH573-671Staining and Labelingbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseStainingchemistryLiver biopsyMolecular MedicineElasticity Imaging TechniquesFemalebusinessTransient elastographyCytologyResearch ArticleAnalytical cellular pathology (Amsterdam)
researchProduct

HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals

2017

Anecdotal reports suggest that patients with chronic hepatitis C virus (HCV) hepatitis and overt or occult hepatitis B virus (HBV) coinfection may reactivate HBV when HCV is suppressed or cleared by direct-acting antivirals (DAAs). We assessed the prevalence of overt or previous HBV coinfection and the risk of HBV reactivation in patients with HCV cirrhosis treated with DAAs. This was a retrospective cohort of 104 consecutive patients with HCV cirrhosis treated with DAAs. Serum HCV-RNA and HBV-DNA were tested at weeks 4, 8 and 12 of DAAs therapy and at week 12 of follow-up. At the start of DAAs, eight patients (7.7%) were HBsAg positive/HBeAg negative with undetectable HBV-DNA and low level…

AdultLiver CirrhosisMaleHepatitis B virusHBsAgCirrhosisHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsVirus03 medical and health sciencesHepatitis B Chronic0302 clinical medicineVirologymedicineHumansHBV-DNA reactivationnucleos(t)ide analogues therapyAgedRetrospective StudiesHepatitisHepatitis B virusHepatologybiologyCoinfectionbusiness.industryvirus diseasesRetrospective cohort studyHepatitis C ChronicMiddle Agedmedicine.diseasebiology.organism_classificationVirologyprevious HBV infectiondigestive system diseasesInfectious DiseasesHBV/HCV coinfection030220 oncology & carcinogenesisDNA ViralCoinfectionRNA ViralFemaleVirus Activation030211 gastroenterology & hepatologysustained virological responsebusiness
researchProduct

Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication

2017

Background & Aims: The risk of hepatocellular carcinoma (HCC) is reduced but not eradicated among patients with hepatitis C virus (HCV)-induced advanced hepatic fibrosis who attained sustained viral response (SVR). We aimed to assess the risk of cirrhosis-related complications in this specific group of patients. Methods: Data from previously reported Western cohort studies including patients with chronic HCV infection and bridging fibrosis or cirrhosis who attained SVR were pooled for survival analyses on the individual patient level. The primary endpoint was HCC and the secondary endpoint was clinical disease progression, defined as liver failure, HCC or death. Results: Included were 1…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularSustained Virologic ResponseHepatitis C virusmedicine.disease_causeGastroenterologyCohort Studies03 medical and health sciencesLiver disease0302 clinical medicineSDG 3 - Good Health and Well-beingRisk FactorsDiabetes mellitusInternal medicinemedicineClinical endpointHumansAgedProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryIncidenceLiver NeoplasmsRetrospective cohort studyHepatitis C ChronicMiddle Agedmedicine.diseasedigestive system diseases030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease Progression030211 gastroenterology & hepatologyFemalebusinessLiver cancer
researchProduct

Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.

2016

Background & Aims: Life expectancy of patients with compensated hepatitis C virus (HCV) cirrhosis achieving sustained virologic response (SVR) is limited by liver events as compared to the general population. Thus, survival benefit of SVR remains to be measured. Methods: The study includes prospective surveillance data from three cohorts of Italian patients with compensated HCV cirrhosis who achieved SVR on an interferon-based (IFN) regimen, compared to simultaneously observed non-SVR, untreated and decompensated patients. Overall survival was calculated from the date of start of IFN to death. The number of deaths expected during the at-risk period was determined by applying age- and se…

AdultLiver CirrhosisMalemedicine.medical_specialtySustained Virologic ResponsePopulation03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProspective StudieseducationSurvival analysisAgededucation.field_of_studyHepatologybusiness.industryMortality rateHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurgerySurvival RateRegimenStandardized mortality ratio030220 oncology & carcinogenesisRelative riskHCVFemale030211 gastroenterology & hepatologyInterferonsViral hepatitisbusiness
researchProduct

Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease St…

2022

Correction to Lancet Gastroenterol Hepatol 2022; 7: 627-47. Lancet Gastroenterol Hepatol. 2022 Aug;7(8):704. doi: 10.1016/S2468-1253(22)00210-2. PMID: 35809605. Background: Colorectal cancer is the third leading cause of cancer deaths worldwide. Given the recent increasing trends in colorectal cancer incidence globally, up-to-date information on the colorectal cancer burden could guide screening, early detection, and treatment strategies, and help effectively allocate resources. We examined the temporal patterns of the global, regional, and national burden of colorectal cancer and its risk factors in 204 countries and territories across the past three decades. Methods: Estimates of incidenc…

AdultMED/42 - IGIENE GENERALE E APPLICATAIMPACTcolorectal cancerColorectal NeoplasmGBD 2019 Colorectal Cancer CollaboratorsHEREDITARYGlobal Burden of DiseaseCancer screeningDISPARITIESSDG 3 - Good Health and Well-beingCancer treatment strategiesRisk FactorsQuality-Adjusted Life YearCOLONGlobal studiesDALY GBD colorectal cancerrisk factorsHumansGlobal Burden of Disease StudyEarly Detection of CancerHepatologyMORTALITYGastroenterologyCancer incidence ratesMiddle AgedCancer burdenSURVIVAL/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSEXGENDERQuality-Adjusted Life YearsColorectal NeoplasmsHumanThe Lancet Gastroenterology & Hepatology
researchProduct

Clinicopathological study of oral focal mucinosis : a retrospective case series

2018

Background Oral focal mucinosis (OFM) is a rare soft tissue lesion of unknown etiology that exhibits tumor-like growth. It is considered the oral counterpart of cutaneous focal mucinosis or cutaneous myxoid cyst. This is a retrospective study of oral OFM diagnosed over a period of 42 years at an oral pathology service. Material and Methods Clinical, histopathological and immunohistochemical data were analyzed. Alcian blue staining and S-100 immunohistochemistry were performed. Results Eleven cases were retrieved (4:1 female-to-male ratio). The mean age was 44 years. The gingiva was the most affected site. The main clinical presentation was sessile or pedunculated lesions of fibrous or hyper…

AdultMale0301 basic medicinePathologymedicine.medical_specialtyMucinosesAsymptomatic03 medical and health sciences0302 clinical medicineOral and maxillofacial pathologymedicineHumansGeneral DentistryAgedRetrospective StudiesOral Medicine and Pathologybusiness.industryResearchDiagnosis OralMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseStaining030104 developmental biologyOtorhinolaryngologyCutaneous focal mucinosisUNESCO::CIENCIAS MÉDICAS030221 ophthalmology & optometryEtiologyImmunohistochemistryFemaleSurgerymedicine.symptomDifferential diagnosisMouth DiseasesMyxoid cystbusiness
researchProduct

Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine

2017

Purpose To investigate the effect of cyclosporine on corneal ultrastructure and on major signs and symptoms of patients with dry eye disease.Patients and methods In this prospective cohort study, patients with dry eye disease were treated with a drop of cyclosporine 0.05% twice daily. Clinical evaluation was carried out at baseline and at months 1, 3, and 6. All patients completed the Ocular Surface Disease Index (OSDI) questionnaire, and tear film break-up time (BUT), fluorescein and lissamine green staining, and Schirmer test were carried out. In vivo confocal microscopy was also performed and epithelial cellular density, keratocyte activation, and subbasal plexus morphology were assessed…

AdultMale0301 basic medicinemedicine.medical_specialtyAdministration TopicalConfocalDry Eye SyndromesGlaucomaCell CountOphthalmic SolutionFollow-Up StudieCorneaImmunosuppressive Agent03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOphthalmologyCorneamedicineOcular Surface Disease IndexFluoresceinProspective cohort studyAgedMicroscopy Confocalbusiness.industryMiddle Agedmedicine.diseaseStainingProspective StudieOphthalmologyTreatment Outcome030104 developmental biologymedicine.anatomical_structureNerve FiberchemistryCyclosporine030221 ophthalmology & optometryFemalebusinessDry Eye SyndromeHumanEye
researchProduct

Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals

2018

The emergence of resistance-associated substitutions (RASs) can compromise the high efficacy of direct-acting antivirals (DAAs). Little is known about RASs selection at very early time points during DAA treatment. Therefore, we analyzed the potential emergence of RASs immediately after therapy initiation. Samples of 71 patients treated with different DAAs were collected at baseline, during therapy (hours 4 and 8; days 1-7; weeks 2-4) or until target not detected. HCV-RNA levels were determined by qPCR, and RASs were detected by deep sequencing. Sixty-three (89%) patients achieved a sustained virological response (SVR), 7 (10%) relapsed, and 1 (1%) experienced a breakthrough. Almost all non-…

AdultMale0301 basic medicinemedicine.medical_specialtySustained Virologic ResponseHepatitis C virusHepacivirusViral quasispeciesReal-Time Polymerase Chain ReactionDIRECT ACTING ANTIVIRALSmedicine.disease_causeAntiviral AgentsGastroenterologyDeep sequencingVirological response03 medical and health sciences0302 clinical medicineRecurrenceGenetic EvolutionVirologyInternal medicineDrug Resistance ViralHumansMedicineProspective StudiesSelection GeneticAgedAged 80 and overHepatologybusiness.industryAntiviral therapyvirus diseasesHepatitis C ChronicMiddle AgedViral Loaddigestive system diseases030104 developmental biologyInfectious DiseasesAmino Acid SubstitutionRNA ViralFemale030211 gastroenterology & hepatologySensitivity limitbusinessJournal of Viral Hepatitis
researchProduct